

ORASURE TECHNOLOGIES INC

Form 8-K

November 17, 2003

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 17, 2003

OraSure Technologies, Inc.

(Exact name of issuer as specified in charter)

DELAWARE	001-16537	36-4370966
(State or Other Jurisdiction of Incorporation or Organization)	(Commission file number)	(I.R.S. Employer Identification Number)

220 East First Street
Bethlehem, Pennsylvania 18015-1360
(Address of principal executive offices)

(610) 882-1820

(Registrant's telephone number, including area code)

Item 5 Other Events and Regulation FD Disclosure.

OraSure Technologies, Inc. (the Company) issued a press release on November 17, 2003, announcing that it will be submitting additional data to the U.S. Food and Drug Administration in support of an HIV-2 claim for the Company's OraQuick® Rapid HIV-1 Antibody Test. The information contained in the press release is incorporated herein by reference and attached to this Current Report on Form 8-K as Exhibit 99.

Item 7. Financial Statements and Exhibits

(c) Exhibits

<u>Exhibit Number</u>	<u>Description</u>
99	Press Release dated November 17, 2003, announcing that OraSure Technologies, Inc. will be submitting additional data to the U.S. Food and Drug Administration in support of an HIV-2 claim for its OraQuick® Rapid HIV-1 Antibody Test.

Index to Exhibits

<u>Exhibit Number</u>	<u>Description</u>
99	Press Release dated November 17, 2003, announcing that OraSure Technologies, Inc. will be submitting additional data to the U.S. Food and Drug Administration in support of an HIV-2 claim for its OraQuick® Rapid HIV-1 Antibody Test.